Using Timolol Solution to Heal Surgical Wounds Faster
Efficacy of Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
This study is testing if a special eye drop solution can help speed up the healing of surgical wounds on the legs after Mohs surgery compared to regular care.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 102 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Icahn School of Medicine at Mount Sinai Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06941467 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a topical 0.5% timolol solution in promoting faster healing of lower extremity wounds resulting from Mohs Micrographic Surgery. It aims to compare the healing time and cosmetic outcomes of wounds treated with timolol against those receiving standard care. The focus is on patients with open surgical wounds that are between 0.5 cm and 4 cm in size, who are scheduled for Mohs surgery. The study will assess whether timolol can significantly reduce the time required for these wounds to heal by secondary intention.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older scheduled for Mohs Micrographic Surgery with specific wound sizes.
Not a fit: Patients with larger wounds, those on certain medications, or with specific health conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could lead to quicker healing times and improved cosmetic results for patients with surgical wounds.
How similar studies have performed: While topical timolol has shown promise in chronic wound healing, this approach for acute surgical wounds is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be scheduled to undergo MMS at 234 East 85th St for a skin cancer that is deemed Mohs * Appropriate by the Mohs surgery appropriate use criteria * Have an open surgical wound \< 4 cm and \> 0.5 cm * Be ≥18 years of age * English-speaking * Provide a signed and dated informed consent form * State willingness to comply with all study procedures Exclusion Criteria: * Age less than 18 years of age * Open surgical wound \> 4 cm * If tumor clearance cannot be achieved with MMS * Pregnant women * Breastfeeding women * Patients who are taking oral beta-blockers (ie oral timolol, metoprolol, carvedilol, propranolol, atenolol) * Patients who are currently taking any of the following medications: clonidine, digoxin, methyldopa, quinidine, fluoxetine and paroxetine, bupropion * Patient currently taking a calcium channel blocker AND has pre-existing heart failure as defined by a reduced ejection fraction * Patients with pre-existing hypotension * Pre-existing diagnosis of sinus bradycardia * Pre-existing diagnosis of second or third degree atrioventricular block * Congestive heart failure * Pre-existing diagnosis of severe asthma * Pre-existing diagnosis of chronic obstructive pulmonary disease * Any known hypersensitivity to 0.5% timolol solution * Patients who have a wound where primary closure is feasible and desired by the patient * Defect size \<0.5 cm * Prior sensitivity or known allergy to timolol
Where this trial is running
New York, New York
- Mount Sinai — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Jesse Lewin, MD — Primary Investigator
- Study coordinator: Jesse Lewin, MD
- Email: jesse.lewin@mountsinai.org
- Phone: 212-731-3316
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.